What is the catalog number for Bulevirtide?

The catalog number for Bulevirtide is HY-P3465.

What sizes are available for Bulevirtide?

Bulevirtide is available in the following size(s): 1 mg, 5 mg, 10 mg, 25 mg.

How many pack sizes does Bulevirtide come in?

Bulevirtide is available in 4 different pack sizes.

Is Bulevirtide in stock?

Bulevirtide is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Bulevirtide?

Bulevirtide is manufactured by QuantiMol.

What is the estimated delivery time for Bulevirtide?

Estimated delivery time for Bulevirtide is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Bulevirtide?

The safety data sheet for Bulevirtide is available here: http://file.medchemexpress.com/batch_PDF/HY-P3465/Bulevirtide-SDS-MedChemExpress.pdf.

Bulevirtide

Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research[1][2].

Product Specifications

CAS Number

2012558-47-1

Product Name Alternative

Myrcludex B

UNSPSC

12352209

Target

HBV

Type

Peptides

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/bulevirtide.html

Purity

99.70

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 83.33 mg/mL (ultrasonic; adjust pH to 8 with NH3·H2O)

Smiles

O=C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](C(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CC(N)=O)C(N2[C@@H](CCC2)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=CC=C4)C(N5[C@@H](CCC5)C(N[C@@H](CC(O)=O)C(N[C@@H](CC6=CNC=N6)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N7[C@@H](CCC7)C(N[C@@H](C)C(N[C@@H](CC8=CC=CC=C8)C(NCC(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(N)=O)C(N9[C@@H](CCC9)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%10=CNC%11=CC=CC=C%10%11)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%12=CC=CC=C%12)C(N[C@@H](CC(N)=O)C(N%13[C@@H](CCC%13)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%14=CNC=N%14)C(N[C@@H](CC%15=CNC%16=CC=CC=C%15%16)C(N%17[C@@H](CCC%17)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(NCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CNC(CCCCCCCCCCCCC)=O

Molecular Formula

C248H355N65O72

Molecular Weight

5398.86

References & Citations

[1]Masetti C, et al. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int. 2021 Jul;41 (7) :1441-1442.|[2]Cheng D, et al. Clinical effects of NTCP-inhibitor myrcludex B. J Viral Hepat. 2021 Jun;28 (6) :852-858.|[3]Donkers JM, et al., Mechanistic insights into the inhibition of NTCP by myrcludex B. JHEP Rep. 2019 Aug 1;1 (4) :278-285.|[4]Volz T, et al., The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013 May;58 (5) :861-7.|[5]Zhao K, et al., Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect. 2018 Nov 21;7 (1) :186.